Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

NCT06518837 on ClinicalTrials.gov · last registry update 2026-01-21

A small phase 2 — 40 participants, against a typical 110. Due to report 30 September 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: Weight Loss Reduction with Tirzepatide during Adjuvant Treatment for HR+/Her2- Breast Cancer (Measured by Body Weight Reduction). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 30 October 2024 — 2 years so far. tirzepatide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Rutgers, The State University of New Jersey
Sponsor type: Other
Enrollment: 40
Started: 2024-10-30
Primary completion: 2027-09-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight Loss Reduction with Tirzepatide during Adjuvant Treatment for HR+/Her2- Breast Cancer (Measured by Body Weight Reduction)

Conditions studied

Hormone Receptor-Positive Breast Cancer · HER2-Negative Breast Cancer

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.